Abstract
Purpose :
To report the effectiveness of a novel device called MGrX (OcuSci), as a palpebral therapy option to reduce signs and symptoms of evaporative dry eye disease (EDED) due to meibomian gland dysfunction (MGD).
Methods :
Case series. Patients with EDED due to MGD presenting varying degrees of ocular surface symptomatology, as well as varying degrees of MGD were subjected to a single session with the MGrX. We recorded their uncorrected visual acuity (UCVA), Ocular Surface Disease Index (OSDI) score, and meibography score (MS) measured with the Me-Check® infrared meibography device before the MGrX session and one month afterwards. MGrX sessions consisted of debridement and scaling of the eyelid margins, application of dry heat and meibomian gland expression. Normality of data was assessed via the Shapiro-Wilk test, and statistical significance between pre and post therapy was evaluated by the Wilcoxon Rank Sum Test.
Results :
24 eyes of 12 patients were included. Patients ages ranged from 13 to 79 years with a mean of 45.66 years. The mean pre-treatment OSDI score was 26.89, with a standard deviation of 9.14. Mean post-treatment OSDI score was 13.29, with a standard deviation of 14.04. This change in OSDI score was statistically significant (p<0.01). However, there was no statistically significant difference between pre-treatment and post-treatment meibographies or UCVA.
Conclusions :
In this case series, the MGrX sessions showed an effective and quick therapy for MGD in patients from a wide range of DED severity. In our study, we noticed a significant decrease in OSDI score one month after a single session. The meibographies did not show an improvement since the device’s main target is the obstruction of the Meibomian glands and not the restoration of glandular architecture, such as Meibomian gland probing. To summarize, the MGrX appears to be a safe, effective, and swift option for the treatment of MGD.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.